Why Generic Antidepressant Cycling Falls Short: Early Augmentation and TD Risk

"Why Generic Antidepressant Cycling Falls Short: Early Augmentation and TD Risk" takes up the decision point every prescriber eventually reaches: switch, augment, or change strategy entirely.

Erin Crown describes the typical patient who reaches her specialty psychiatry practice: someone who has been depressed for months or years, often already tried psychotherapy, and usually already failed one or two generic antidepressants, since US healthcare systems generally require that step first. She tells patients there is little evidence supporting continuous switching within or between classes of generic antidepressants; starting an SSRI, optimizing to the correct dose, then swapping to another SSRI or an SNRI rarely produces a meaningfully different outcome. She distinguishes optimal dose from maximum dose, noting that pushing past optimal dose rarely adds therapeutic benefit but reliably adds adverse events. SNRIs, she adds, behave largely like SSRIs until higher doses introduce meaningful noradrenergic reuptake inhibition.

Rather than repeating the same mechanism, Erin Crown says she moves early toward either a branded medication with a genuinely different mechanism, such as a dextromethorphan-bupropion combination, or early augmentation. Augmenting with an atypical antipsychotic roughly doubles the likelihood of remission compared with an antidepressant alone, and it lets her build on progress a patient has already made rather than risking it in a straight switch, while introducing multimodal activity against a heterogeneous illness. Before choosing an augmentation agent, though, Erin Crown weighs each patient's inherent risk for tardive dyskinesia. She lists specific risk factors she screens for: age over 60, post-menopausal status, a history of substance use, neurodegenerative disorders, autism, and, notably, having a mood disorder itself. Those risk factors, taken together, help determine both whether to augment and which agent to choose, since available options vary in how much TD risk they carry for a given patient's clinical profile.

In "The Best Medication Is the One Patients Take: Weighing Augmentation Risks," Dr. Harding and Dr. Citrome examine how guideline thresholds, side-effect profiles, and polypharmacy concerns shape the decision to augment.